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de Montpellier, Institut de Recherche pour le Développement, INSERM, Montpellier, France, 7 Institut de
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Abstract
Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are
commonly transmitted to naive patients. The standard approach to reveal new DRMs is to
test for significant frequency differences of mutations between treated and naive patients.
However, we then consider each mutation individually and cannot hope to study interactions
between several mutations. Here, we aim to leverage the ever-growing quantity of high-
quality sequence data and machine learning methods to study such interactions (i.e. epista-
sis), as well as try to find new DRMs.
We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-
experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence
dataset from the UK (n� 55, 000), using all observed mutations as binary representation
features. To assess the robustness of our findings, our classifiers were evaluated on inde-
pendent data sets, both from the UK and Africa. Important representation features for each
classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this pro-
cess by removing either features or samples associated to known DRMs.
When keeping all known resistance signal, we detected sufficiently prevalent known
DRMs, thus validating the approach. When removing features corresponding to known
DRMs, our classifiers retained some prediction accuracy, and six new mutations signifi-
cantly associated with resistance were identified. These six mutations have a low genetic
barrier, are correlated to known DRMs, and are spatially close to either the RT active site or
the regulatory binding pocket. When removing both known DRM features and sequences
containing at least one known DRM, our classifiers lose all prediction accuracy. These
results likely indicate that all mutations directly conferring resistance have been found, and
that our newly discovered DRMs are accessory or compensatory mutations. Moreover,
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apart from the accessory nature of the relationships we found, we did not find any significant
signal of further, more subtle epistasis combining several mutations which individually do
not seem to confer any resistance.
Author summary
Almost all drugs to treat HIV target the Reverse Transcriptase (RT) and Drug resistance
mutations (DRMs) appear in HIV under treatment pressure. Resistant strains can be
transmitted and limit treatment options at the population level. Classically, multiple statis-
tical testing is used to find DRMs, by comparing virus sequences of treated and naive pop-
ulations. However, with this method, each mutation is considered individually and we
cannot hope to reveal any interaction (epistasis) between them. Here, we used machine
learning to discover new DRMs and study potential epistasis effects. We applied this
approach to a very large UK dataset comprising� 55, 000 RT sequences. Results robust-
ness was checked on different UK and African datasets.
Six new mutations associated to resistance were found. All six have a low genetic bar-
rier and show high correlations with known DRMs. Moreover, all these mutations are
close to either the active site or the regulatory binding pocket of RT. Thus, they are good
candidates for further wet experiments to establish their role in drug resistance. Impor-
tantly, our results indicate that epistasis seems to be limited to the classical scheme where
primary DRMs confer resistance and associated mutations modulate the strength of the
resistance and/or compensate for the fitness cost induced by DRMs.
Introduction
Drug resistance mutations (DRMs) arise in Human Immunodeficiency Virus-1 (HIV-1) due
to antiretroviral treatment (ART) pressure, leading to viral rebound and treatment failure [1,
2]. Furthermore, drug-resistant HIV strains can be transmitted to treatment-naive individuals
and further spread throughout the population over time [3–5]. These transmitted resistant var-
iants limit baseline treatment options and have clinical and public health implications world-
wide. Almost all drugs to treat HIV target the reverse transcriptase (RT), encoded by the pol
gene. Lists of DRMs are regularly compiled and updated by experts in the field, based on geno-
type analyses and phenotypic resistance tests or clinical outcome in patients on ART [6–8].
However, with the developement of new antiretroviral drugs that target RT but also other
regions of the pol gene like protease or integrase, and the use of anti-retrovirals in high risk
populations by pre-exposure prophylaxis (PREP), it is important to further our understanding
of HIV polymorphisms and notably the interactions between mutations and epistatic effects.
Among known DRMs, some mutations, such as M184V, directly confer resistance to anti-
retrovirals, more precisely the commonly used NRTI, 3TC (lamivudine) and FTC (emtricita-
bine), and are called primary or major drug resistance mutations, while some mutations like
E40F have an accessory role and increases drug resistance when appearing alongside primary
DRMs. Moreover, some mutations like S68G seem to have a compensatory role, but are not
known to confer any resistance nor modulate resistance induced by primary DRMs. All of
these mutations might have different functions in the virus, but they are all known to be associ-
ated with drug resistance phenomena. Therefore, during the rest of this article we will refer to
all of these known mutations as resistance associated mutations (RAMs), rather than DRMs
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which is too specific, and our goal will be to search for new RAMs and study the interactions
between known RAMs and the new ones.
Classically, new RAMs have been found using statistical testing and large multiple sequence
alignments (MSA) of the studied protein [9, 10]. Tests are performed for mutations of interest
on a given MSA to check if they are associated with the treatment status and outcome of the
individual the viral sequences were sampled from. The test significance is corrected for multi-
ple testing as all mutations associated to every MSA position is virtually a resistance mutation
and tested. After this preliminary statistical search, the selected mutations are scrutinized to
remove the effects of phylogenetic correlation (i.e. typically counting two sequences which are
identical or closely related due to transmission rather than independent acquisition twice [11])
and check that the same mutation occurred several times in different subtypes and populations
being treated with the same drug. Then, these mutations can be further experimentally tested
in vitro or in vivo to validate phenotypic resistance. This method has worked well, but by
design it is not ideal for studying the effect of several mutations at once, since if we have to test
all couples or triplets of mutations, we quickly lose statistical power when correcting for multi-
ple testing [12], due to the large number of tests to perform. Moreover, phylogenetic correla-
tion is again a critical issue with such an approach.
Machine learning has been extensively used to predict resistance to antiretrovirals from
sequence data. There are two main approaches to predicting resistance from sequence data.
Regression, where machine learning models are trained to predict the value of a drug resis-
tance indicator, typically IC50 fold change in response to a given drug [13] or other indicators
from phenotypic resistance assays such as PhenoSense [14]. Many methods have been used to
predict a resistance level: Support Vector Machines (SVMs) [15], k-Nearest Neighbors (KNN)
and Random Forests (RFs) [16], and more recently Artificial Neural Networks (ANNs) [17,
18]. Alternatively, this task has also been approached as a classification problem. Given a cer-
tain threshold on a phenotypic resistance measure, sequences are given a label of “resistant” or
“susceptible” to a certain drug. Machine learning classifiers are then trained to predict that
label. For this task, SVMs and decision trees have been used [19, 20], ensemble classifier chains
[21, 22] and also ANNs [23]. Most recently Steiner et al. [24] have used Deep Learning Archi-
tectures to predict resistance status (i.e. classification) from sequence data. Since phenotypic
assays are more complicated and costly to perform than simple genotyping, there is a limited
number of sequences paired with a resistance level. This is the main limitation of these studies
since machine learning methods typically benefit from a large amount of training data. This is
especially true for deep neural networks which can need hundreds of thousands of training
samples for certain tasks and architectures. However, despite this limitation, approaches pro-
posed in these studies seem to have fairly good predictive accuracy. It is important to note that
all of these studies aim to predict if a given sequence is resistant or not to a given drug, they do
not aim to find new potential RAMs. Although Steiner et al. [24] have checked that known
DRM positions are captured by their models and found several positions potentially associated
to resistance, it is not the main goal of their method.
It is accepted in machine learning that there is a trade-off between model accuracy and
model interpretability. In these previous studies the goal was to make the most accurate pre-
dictions possible, using complex models such as SVMs and ANNs, therefore sacrificing
interpretability. Here, we have a different approach, using simpler models that might be less
accurate but whose predictions we can understand and interpret. We train these models to dis-
criminate RTI-naive from RTI-experienced sequences. Without the need for phenotypic data,
we are able to use much larger HIV-1 RT sequence datasets from the UK (n� 55, 000) (http://
www.hivrdb.org.uk/) and Africa (n� 4, 000) [10]. By using interpretable models, we can
extract mutations that are important for determining if a sequence is treated or not and
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potentially find new mutations potentially associated to resistance. Furthermore, we aim to
detect associations between mutations and their effect on antiretroviral resistance in order to
study potential underlying epistasis. The African and UK datasets are very different both from
genetic and treatment history standpoints, therefore training classifiers on the UK dataset and
testing them on the African one, should guarantee the robustness of our findings and greatly
alleviate phylogenetic correlation effects. In the following sections, we first describe the data
then the methods used. Our results include the assessment of the performance of our classifiers
even when trained on data devoid of any known resistance-associated signal; as well as a
description of the main features (prevalence and correlation to known mutations, genetic
barrier and structural analysis) of six potentially resistance associated mutations, newly discov-




In this study, we used all the drug resistance mutations that appeared in the Stanford HIV
Drug resistance database, both for NRTI (Nucleoside Reverse Transcriptase Inhibitors; https://
hivdb.stanford.edu/dr-summary/comments/NRTI/) and NNRTI (Non Nucleoside RTI;
https://hivdb.stanford.edu/dr-summary/comments/NNRTI/) as known RAMs. To discover
new RAMs, assess their statistical significance and study potential epistatic effects, we used two
datasets of HIV-1 RT sequences. A large one (n = 55, 539) from the UK HIV Drug Resistance
Database (http://www.hivrdb.org.uk/) and a smaller (n = 3, 990) one from 10 different western,
eastern and central African countries [10]. In the UK dataset, sequences from RTI-naive indi-
viduals formed the majority class with 41,921 sequences (75%). In the African dataset, both
classes were more balanced with 2,316 RTI-naive sequences (58%). In the UK dataset, RTI-
naive sequences had at least one known RAM in 25% of cases, most likely due to transmissions
to naive patients or undisclosed treatment history, against 48% in RTI-experienced sequences,
thus making the discrimination between the RTI-experienced and RTI-naive sequences partic-
ularly difficult. In the African dataset this distribution was more contrasted, with only 14%
of RTI-naive sequences having at least one known RAM, versus 83% of RTI-experienced
sequences. The African dataset was also much more genetically diverse with 24 different sub-
types and CRFs compared to the 2 subtypes (B and C) that we retained for this study from the
UK cohort. The majority of the sequences from the African dataset were samples from Camer-
oon (27%), Democratic Republic of Congo (17%), Burundi (15%), Burkina Faso (13%) and
Togo (11%).
It is important to note that RTI-experienced sequences in both of these datasets can be
considered as resistant to treatment. Since the viral load was sufficiently high to allow for
sequencing of the virus, we can consider that the ART has failed. However, in some cases this
resistance might be caused by non adherence to ART, rather than by the presence of RAMs,
therefore adding some noise to the relationship between treatment status and resistance.
In addition to differences in size, balance between RTI-naive and experienced classes, and
the genetic difference between the UK and African datasets, there are also significant differ-
ences resulting from differing treatment strategies. In the UK and other higher income coun-
tries, the treatment is often tailored to the individual with genotype testing, which result in
specific treatment as well as thorough follow-ups and high treatment adherence. In the African
countries of the dataset that we used, the treatment is ZDV/ d4T (NRTI) + 3TC (NRTI) +
NVP/EFV (NNRTI) in most cases [10], and this treatment is generalized to the affected popu-
lation, with poorer follow-up and adherence than in the UK. This discrepancy could lead to
PLOS COMPUTATIONAL BIOLOGY Using machine learning and big data to explore the drug resistance landscape in HIV
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008873 August 26, 2021 4 / 21
different mutations arising in both datasets, however since the treatment strategy is a combina-
tion of both NRTI and NNRTI drug classes, as in many countries, similar RAMs arise [10].
Furthermore, there is potentially more uncertainty in the African dataset than in the UK. For
example some individuals may have unofficially taken antiretroviral drugs, but still identify
themselves as RTI-naive, or report having some form of ART while not having been treated
for HIV [25]. All of this explains the high prevalence of multiple resistance in the African data
set: the median number of RAMs in sequences containing at least one RAM is 3 in the African
sequences, while it is 1 in UK sequences (Table 1). Thus, we can say that African sequences are
highly resistant, with possibly different mutations and epistatic effects, compared to their UK
counterparts.
All these differences between the two datasets helped us to assess the generalizability of our
method and the robustness of the results. That is to say, if signal extracted from the UK dataset
was still relevant on such a different dataset as the African one, we could be fairly reassured in
regard to the biological and epidemiological relevance of the observed signal.
Sequences in both African and UK datasets were already aligned. In order to avoid overly
gappy regions of our alignment we selected only positions 41 to 235 of RT for our analysis. We
used the Sierra web service (https://hivdb.stanford.edu/page/webservice/) to get amino acid
positions relative to the reference HXB2 HIV genome. This allowed us to determine all the
amino acids present at each reference position in both datasets, among which we distinguished
the “reference amino acids” for each position, corresponding to the B and C subtype reference
sequences obtained from the Los Alamos sequence database (http://www.hiv.lanl.gov/). All the
other, non-reference amino acids are named “mutations” in the following, and the set of muta-
tions was explored to reveal new potential RAMs.
To train our supervised classification methods [26–28], the sequence data needed to be
encoded to numerical vectors. A common and intuitive way to do so is to create a single fea-
ture in the dataset for each position of the sequence to encode. Each amino acid is then
assigned an integer value, and an amino acid sequence is represented by a succession of inte-
gers corresponding to each amino acid. There is, however, one drawback with this method: by
assigning an integer value to amino acids, we transform a categorical variable into an ordinal
Table 1. Summary of the UK and African datasets.
UK Africa
size 55539 3990
RTI naive with known RAMs 11429 (21%) 318 (8%)
without known RAMs 30492 (55%) 1998 (50%)
RTI experienced with known RAMs 6633 (12%) 1388 (35%)
without known RAMs 6985 (13%) 286 (7%)
sequences with� 2 known RAMs 8034 (14%) 1308 (33%)
max known RAM number 13 17
Median known RAM number 1 3
number of subtypes / CRFs 2 24
subtypes / CRFs A 0 (0%) 472 (12%)
B 37806 (68%) 64 (2%)
C 17733 (32%) 702 (18%)
CRF02 AG 0 (0%) 1477 (37%)
Percentages are computed with regards to the size of the considered dataset (e.g. 21% of the sequences of the UK dataset are RTI-naive and have at least one known
RAM). The median number of RAMs was computed only on sequences that had at least one known RAM.
https://doi.org/10.1371/journal.pcbi.1008873.t001
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variable. Any ordering of amino acids is hard to justify and might introduce bias. To avoid
this, we represented each sequence by a binary vector using one-hot encoding. For each posi-
tion in the sequence to be encoded, amino acids corresponding to mutations are mapped to a
binary vector denoting its presence or absence in the sequence. For example, at site 184, amino
acids M, G, I, L, T and V are present in the UK dataset. After encoding we will have 5 binary
features corresponding to the M184G, M184I, M184L, M184T and M184V mutations. We did
not encode the reference amino acid M, but only the mutated amino acids. With this method
each mutation in the dataset (n = 1, 318) corresponds to a single feature. Some of these features
corresponded to known RAMs (e.g., M184I and M184V) and are named (known) RAM fea-
tures in the following (n = 121). This encoding allows the classifiers to consider specific muta-
tions and potentially link them to resistance.
Classifier training
In order to find new potential RAMs, we first followed the conventional multiple testing
approach [10]. We first used Fisher exact tests to identify which of these mutations were signif-
icantly associated with anti-retroviral treatment. All the resulting p-values were then corrected
for multiple testing using the Bonferroni correction [29]. Those for which the corrected p-
value was� 0.05 were then considered as significantly associated with treatment and poten-
tially implicated in resistance.
This method was complemented by our parallel, machine learning based approach. In
order to extract potential RAMs, we trained several classifiers to discriminate between RTI-
experienced and RTI-naive sequences represented by the binary vectors described above. This
classification task does not need any phenotypic resistance measure, allowing us to use much
larger and more readily available datasets than other machine learning based approaches pre-
viously mentioned. Once the classifiers were trained, we extracted the most important repre-
sentation features, which corresponded to potentially resistance-associated mutations (PRAM
in short). To this aim we chose three interpretable supervised learning classification methods
so as to be able to extract those features:
1. Multinomial naive Bayes (NB), which estimates conditional probabilities of being in the
RTI-experienced class given a set of representation features [30]; the higher (� 1.0) and the
lower (� 0) conditional probabilities correspond to the most important features.
2. Logistic regression (LR) with L1 regularization (LASSO) [26] which assigns weights to each
of the features, whose sign denotes the importance to one of the 2 classes, and whose abso-
lute value denotes the weight of this importance.
3. Random Forest (RF), which has feature importance measures based on the Gini impurity
in the decision trees [31].
Interpretability was the main driver behind our classification method choice, with the con-
ditional probabilities of NB, the weight or LR and the importance values of RF, we can easily
extract which mutations are driving the discrimination of RT sequences. This is why we did
not choose to use ANNs which could have led to an increase in accuracy at the cost of
interpretability [32–34]. Moreover, these three classification methods have the potential to
detect epistatic effects. With RF, the discrimination is based on the combination of a few fea-
tures (i.e. mutations), while with LR the features are weighted positively or negatively, thus
making it possible to detect cumulative effects resulting from a large number of mutations,
which individually have no discrimination power. Naive Bayes is a very simple approach, gen-
erally fairly accurate, and in between the two others in terms of explanatory power [28].
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In order to be able to compare all these approaches in a common framework, we devised a
very simple classifier out of the results of the Fisher exact tests. This “Fisher classifier” (FC)
predicts a sequence as RTI-experienced if it has at least one of the mutations significantly asso-
ciated to treatment. In this way, we were able to compute metrics for all classification methods
and compare their performance.
It is important to note that in all of these approaches we chose to discriminate RTI-naive
from RTI-experienced sequences, regardless of the type of RTI received. One of the reasons is
that we did not have detailed enough treatment history for sequences in the UK and African
datasets. Moreover, even without segmenting by treatment type, the size of the training set and
the power of our classification methods were both high enough to be able to detect all kinds of
resistance associated mutations. We shall see (Result section) that we were able to determine
the likely treatment involved by further examining the important extracted features and com-
paring them to known RAMs. Furthermore, since the treatment strategies are so different
between the UK and African sequences, training on sequences having received different treat-
ments should increase the robustness of our classifiers and the relevance of the mutations
selected as potentially associated to resistance.
To avoid phylogenetic confounding factors (e.g. transmitted mutations within a specific
country or region), and avoid finding mutations potentially specific to a given subtype, we
split the training and testing sets by HIV-1 M subtype. This resulted in training a set of classifi-
ers on all subtype B sequences of the UK dataset and testing them on subtype C sequences
from the UK dataset, training another set of classifiers on the subtype C sequences of the UK
dataset and testing on the subtype B sequences from the UK dataset, as well as training a final
set of classifiers on the whole UK dataset, but testing it on the smaller African dataset with a
completely different phylogenetic makeup and treatment context [10]. Furthermore, in order
to identify novel RAMs and study the behavior of the classifiers, we repeated this training
scheme on both datasets, each time removing resistance-associated signal incrementally: first
by removing all representation features corresponding to known RAMs from the dataset, and
second by removing all sequences that had at least one known RAM. This resulted in each type
of classifier being trained and tested 9 times, on radically different sets to ensure the interpret-
ability and robustness of the results (see Table 2).
Measuring classifier performance
To compare the performance of our classifiers we used balanced accuracy [35], which is the
average of accuracies (i.e. percentages of well-classified sequences) computed separately on
Table 2. All training and testing datasets used during this study.
Signal removal level Trained on Tested on
None UK, subtype B (37806) UK, subtype C (17733)
UK, subtype C (17733) UK, subtype B (37806)
UK, subtypes B & C (55539) Africa, all subtypes (3990)
Known RAM features removed UK, subtype B (37806) UK, subtype C (17733)
UK, subtype C (17733) UK, subtype B (37806)
UK, subtypes B & C (55539) Africa, all subtypes (3990)
Known RAM features & sequences with�1 known RAM removed UK, subtype B (24422) UK, subtype C (13055)
UK, subtype C (13055) UK, subtype B (24422)
UK, subtypes B & C (37477) Africa, all subtypes (2284)
The number of sequences in each dataset is shown in parentheses
https://doi.org/10.1371/journal.pcbi.1008873.t002
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each class of the test set. This score takes into account, and corrects for, the imbalance between
RTI-naive and RTI-experienced samples, which would lead to a classifier always predicting a
sequence as RTI-naive getting a classical accuracy score of up to 77% (i.e. the frequency of
naive sequences in the UK dataset). We also computed the adjusted mutual information
(AMI) between predicted and true sequence labels, which is a normalized version of MI
allowing comparison of performance on differently sized test sets [36]. Additionally, mutual
information (MI) was used to compute p-values and assess the significance of the classifiers’
predictive power. The probabilistic performance of the classifiers was evaluated using an
adapted Brier score [27] more suited to binary classification, which is the mean squared differ-
ence between the actual class (coded by 1 and 0 for the RTI-experienced and RTI-naive sam-
ples respectively) and the predicted probability of being RTI-experienced. This approach
refines the standard accuracy measure by rewarding methods that well approximate the true
status of the sample (eg. predicting a probability of 0.9 while the true status is 1); conversly,
binary methods (predicting 0 or 1, but no probabilities) will be penalized if they are often
wrong. The Brier approach thus assigns better scores to methods that recognize their igno-
rance than to methods producing random predictions.
Results
Classifier performance & interpretation
As can be seen in Fig 1A and 1B, when all RAM features and sequences were kept in the train-
ing and testing sets, classifiers had good prediction accuracy, with the machine learning classi-
fiers slightly outperforming the “Fisher” classifier. When removing RAM features from the
training and testing sets, the classifiers retained a significant prediction accuracy, especially
with the African data set and its multiple RAMs that are observed in a large number of
sequences (but removed in this experiment). In this configuration the ML classifiers had a
similar performance to the “Fisher” classifier, except for the random forest that is slightly less
accurate, likely due to overfitting. Also, when removing sequences that had known RAMs,
every classifier lost all prediction accuracy, and none could distinguish RTI-naive from RTI-
experienced sequences. Regarding the Brier sore, we see the advantage of the machine learning
classifiers over the “Fisher” classifier, which is worse than random predictions when known
RAMs are removed. The ability of machine learning classifiers to quantify the resistance status
should be an asset for many applications.
The fact that classifiers retained prediction accuracy after removing known RAM corre-
sponding features suggests that there was some residual, unknown resistance-associated signal
in the data. The fact that this same power was non-existent when removing the known RAM-
containing sequences from the training and testing sets, indicates that this residual signal was
contained in these already mutated sequences. This suggests that the mutations that are found
in the RAM removed experiment (see list below) are most likely accessory mutations that
accompany known RAMs. This also suggests that all primary DRMs (i.e., that directly
confer antiretroviral resistance) have been identified, which is reassuring from a public health
perspective.
The performance discrepancy between the UK and African test sets can be explained by
several factors. Firstly, African sequences that have known RAMs are more likely to have mul-
tiple RAMs, and thus more (known and unknown) resistance-associated features than their
UK counterparts (c.f. Table 1). This means that resistant African sequences are easier to detect
even when removing known RAMs. Secondly, RTI-naive sequences in the UK test sets are
more likely to have known RAMs than their African counterparts (c.f. Table 1) and therefore
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more companion mutations. This means that the RTI-naive sequences in the UK test set are
more likely to be misclassified as RTI-experienced than in the African test set.
Additional classification results
The fact that, when looking at classifiers trained without known RAMs, “Fisher” classifiers
perform as well as the machine learning ones, leads us to believe that there is little interaction
between mutations that would explain resistance better than taking each mutation separately.
It is therefore likely that the kind of epistatic phenomena we were looking for, combining sev-
eral mutations that do not induce any resistance when taken separately, do not come into play
Fig 1. Classifier Performance on UK and African datasets. NB: naive Bayes, LR: Logistic Regression with Lasso regularization, RF: Random Forest, FC:
Fisher Classifier, RD: Agnostic random probabilistic classifier (this classifier predicts, as the probability of a sample belonging to a class, the frequency of
that class in the training data). A) Adjusted mutual information (higher is better) between ground truth and predictions by classifiers trained on dataset
with all features (blue), without features corresponding to known RAMs (orange) and without RAM features and without sequences that have at least 1
known RAM (green). Hatching indicates the training set on which a classifier was trained and the testing set on which the performance was measured. The
expected value for a null classifier is 0, and 1 for a perfect classifier and a � denotes that the p-value derived from mutual information is� 0.05. For example
when trained with all features all the classifiers have a significative MI. Conversely when removing RAM features and RAM sequences none of the classifiers
have a significative MI and only LR trained on the entirety of the UK dataset has an AMI>10−3. B) Balanced Accuracy score, i.e. average of accuracies per-
class (higher is better) for the same classifiers as in A). The red line at y = 0.5 is the expected balanced accuracy for a null classifier that only predicts the
majority class as well as a random uniform (i.e. 50/50) classifier. C) Brier score, which is the mean squared difference between the sample’s experience to
RTI and the predicted probability of being RTI experienced (lower is better), for the same classifiers as in A) and B).
https://doi.org/10.1371/journal.pcbi.1008873.g001
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here. We are in a classical scheme where primary DRMs confer resistance and associated
mutations reinforce the strength of the resistance and/or compensate for the fitness cost
induced by primary DRMs.
It is important to remember that in the previous section we were trying (as usual, e.g. see
[10]) to find novel mutations associated with resistance by discriminating RTI-naive from
RTI-experienced sequences, both with the statistical tests and the classifiers. However, this is
intrinsically biased and noisy. Indeed, a RTI-naive sequence is not necessarily susceptible to
RTIs as a resistant strain could have been transmitted to the individual. Conversely, an RTI-
experienced sequence may not be resistant to treatment, due to poor ART adherence for exam-
ple. We must therefore keep in mind that the noisy nature of the relationship between resis-
tance and treatment status is partly responsible for the lower performance of classifiers trained
on the UK sequences with reduced signal.
Moreover, as all the additional resistance signal we detected is associated to the sequences
having at least one known RAM (see above), we performed another analysis trying to dis-
criminate between the sequences having at least one known RAM and those having none.
The goal was to check that the mutations we discovered by discriminating RTI-experienced
from RTI-naive samples, are truly accessory and compensatory mutations. As can be seen
in Fig 2A and 2B, the classifiers trained to discriminate sequences that have at least one
known RAM from those that have none, on datasets from which all features corresponding
to known RAMs were removed, perform much better than classifiers trained to discriminate
RTI-experienced from RTI-naive sequences. This increase in performance is especially visi-
ble for classifiers tested on UK sequences (more difficult to classify than the African ones, see
above), with an AMI often almost one order of magnitude higher for the known-RAM pres-
ence/absence classification task. This further reinforces our belief that all there is a fairly
strong residual resistance-signal in sequences that contain known RAMs, due to new acces-
sory and compensatory mutations identified by our classifiers and Fisher tests. As a side
note, Logistic regression (LR) consistently outperforms other classifiers, a tendency already
observed in Fig 1.
Identifying new mutations from classifiers
We assessed the importance of each mutation in the learned internal model of all the classifi-
ers, in the setting where all known RAMs have been removed from the training dataset. For
the Fisher classifier, we used one minus the p-value of the exact Fisher test as the importance
value, therefore the more significantly associated mutations have the higher importance value
and were ranked first. For a given classification task, we ranked each mutation according to
the appropriate importance value for each classifier (see above), trained on the B or C subtypes,
with the highest importance value having a rank of 0. We then computed the average rank for
each mutation and each classification task (RTI-naive/RTI-experienced and RAM present/
RAM absent). This gave us, for each classification task, a ranking of mutations potentially asso-
ciated with resistance that took into account the importance given to this new mutation by
each classifier trained on this task. Mutations that were in the 10 most important mutations
for both of the classification tasks were considered of interest. Based on these criteria we
selected the following potentially resistance-associated mutations (w.r.t. the HXB2 reference
genome): L228R, L228H, E203K, D218E, I135L and H208Y. These mutations are referred to as
“new mutations” in the rest of this study.
To check the epistatic nature of these selected mutations we computed the relative risk
RR(new, X) between a new mutation and a binary character X. RR(new, X) was computed
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from the contingency table between new and X as follows:
X present X absent
new present A B






The RR gives us a measure for how over-represented each of our new mutations is in
sequences that have the X character compared to those that don’t.
To get a general idea of this over-representation, for each new mutation we computed
RR(new, treatment) comparing the prevalence of the new mutation in RTI-experienced and
RTI-naive sequences. We also computed RR(new, any RAM) comparing the prevalence the
new mutation in sequences having at least one known RAM and sequences that have none.
Both of these RRs are shown in Table 3 for each new mutation.
We then computed RR(new, RAM) for each known RAM present in more than 0.1% of UK
sequences and the new mutations. In Fig 3 we see the RRs for which the lower bound of the
95% confidence interval, computed on 1000 bootstrap samples from the UK dataset, was
greater than 4.
Detailed analysis of potentially resistance-associated mutations
As can be seen in Table 3, all of these new mutations except for I135L, are highly over-repre-
sented in RTI-experienced sequences and sequences that already have known RAMs, with
lower bounds on the 95% RR CI always greater than 5, and often exceeding 10. When looking
Fig 2. Discrimination between sequences having at least one RAM, and those having none on sequences with
training features corresponding to known RAMs removed. NB: naive Bayes, LR: Logistic Regression with Lasso
regularization, RF: Random Forest, FC: Fisher Classifier. A) Adjusted mutual information (higher is better) for
classifiers trained without features corresponding to known RAMs. The classifiers are either trained to discriminate
RTI-naive from RTI-experienced sequences (blue), or sequences with at least one known RAM from sequences that
have none (orange). Hatching and braced annotations indicate the training and testing sets resulting in a given
performance measure. B) Balanced accuracy, i.e. average of accuracies per-class for the same classifiers as in A) (higher
is better). The red line at y = 0.5 is the expected value for a classifier only predicting the majority class as well as a
random uniform (50/50) classifier.
https://doi.org/10.1371/journal.pcbi.1008873.g002
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at the RRs computed for individual RAMs on the UK dataset (Fig 3), this impression is con-
firmed with very high over-representation of these new mutations potentially associated with
resistance in sequences that have a given known RAM, with 95% RR lower CI bounds some-
times greater than 80 (H208Y/L210W and D218E/D67N), and most of the time greater than
10. with the noticeable exception of I135L where only 2 known RAMs give RRs with lower CI
bounds greater than 4. The RRs computed on the African dataset (S1 Fig) tell a similar story
albeit with smaller RR values due to a smaller number of occurrences of both new mutations
and known RAMs.
The genetic barrier to resistance for each of these new mutations is quite low, with a mini-
mum of 1 base change for each of them (Table 3). We also computed the average codon dis-
tance (i.e. number of different bases), weighted by the prevalence of wild and mutated
codons at the given positions in the UK (Table 3) and Africa (S1 Table) datasets, and in each
case the average codon distance was always close to 1. In other words, at the amino acid level
these mutations are expected to be relatively frequent. However, their frequencies are much
higher in treated/with-RAM sequences than in naive/without-RAM ones (Table 3). More-
over, if we look at the BLOSUM62 scores (Table 3), some of these mutations induce some
substantial changes in physicochemical properties, most notably at site 228, which reinforces
again the likelihood that these mutations are associated with resistance. These metrics were
also computed for all known RAMs (Table 3). For all these metrics, and the 6 new potential
Table 3. Analysis of new potential RAMs.
codon distance UK
RR(new, X)
min avg B62 count treatment any RAM p-value
L228R 1 1.16 -2 227 (0.4%) 18.1 115.7 3.4 � 10−31
[12.9;27.3] [55.1;507.3]
E203K 1 1.31 1 256 (0.5%) 11 20.1 1.1 � 10−14
[8.2;15.1] [13.7;32.1]
D218E 1 1 2 168 (0.3%) 13.1 27 3.3 � 10−10
[9.0;19.6] [16.3;57.0]
L228H 1 1.12 -3 287 (0.5%) 6.4 9.2 4.4 � 10−16
[5.1;8.4] [6.9;12.6]
I135L 1 1.16 2 540 (1.0%) 1.8 2.4 5.9 � 10−08
[1.5;2.1] [2.0;2.8]
H208Y 1 1.10 2 205 (0.4%) 8.8 14.9 1.2 � 10−05
[6.5;12.5] [9.9;23.6]
RAMs 1 1.35 0 58 (0.1%) 8.3 26.4 3.1 � 10−2
[1;2] [1;2.44] [-2;3] [2;1842] [0.6;1] [1.4;1] [2.3 � 10−58;1]
Codon distance: For each new mutation we computed the minimum number of nucleotide mutations to go from the wild amino acid codons to those of the mutated
amino acid, as well as the average codon distance between both amino acids, weighted by the prevalence of each wild and mutated codon at the given position in the UK
dataset. B62: BLOSUM62 similarity values (e.g. D218E = 2, reflecting that E and D are both negatively charged and highly similar). Count: We looked at the number of
occurrences of each new potential RAM in the UK dataset and the corresponding prevalence in parentheses. Relative risks: We computed RR(new, treatment) (e.g.
L228R is 18.1 times more prevalent in RTI-experienced sequences compared to RTI-naive sequences in the UK dataset). We also computed RR(new, any RAM) (e.g.
L228R is 115.7 times more prevalent in sequences that have at least one known RAM than in sequences that have none in the UK dataset). The 95% confidence intervals
shown under each RR were computed with 1000 bootstrap samples of size n = 55, 000 drawn with replacement from the whole UK dataset. p-values: Fisher exact tests
were done on the African dataset (to avoid confounding effects due to phylogenetic correlation) to see if each of these new mutations were more prevalent in RTI-
experienced sequences. The same metrics were computed for all known RAMs, the median values are shown in the last two lines of this table, as well as the 5th and 95th
percentiles which are shown underneath. RR(RAM, any RAM) values were computed for any RAM except itself to avoid always having infinite ratios.
https://doi.org/10.1371/journal.pcbi.1008873.t003
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RAMs, values are contained between the 5th and 95th percentiles computed on known
RAMs, except for the BLOSUM score of L228H that corresponds to a drastic physicochemi-
cal change.
To gain more insight on these new mutations we also observed their spatial location on the
3-D HIV-1 RT structure using PyMol [37]. HIV-1 RT is a heterodimer with two subunits
translated from the same sequence with different lengths and 3-D structures. The smaller p51
subunit (440 AAs) has a mainly structural role, while the larger p66 (560 AAs) subunit has the
active site at positions 110, 185 and 186. The p66 subunit also has a regulatory pocket behind
Fig 3. Relative risk of the new mutations with regards to known RAMs on the UK dataset. (i.e. the prevalence of the new mutation in sequences with a
given known RAM divided by the prevalence of the new mutation in sequences without this RAM). RRs were only computed for mutations (new and
RAMs) that appeared in at least 0.1% (=55) sequences. 95% confidence intervals, represented by vertical bars, were computed with 1000 bootstrap samples
of UK sequences. Only RRs with a lower CI boundary greater than 4 are shown. The shape and color of the point represents the type of RAM as defined by
Stanford’s HIVDB. Blue circle: NRTI, orange square: NNRTI, green diamond: Other. RR values are shown from left to right, by order of decreasing values
on the lower bound of the 95% CI.
https://doi.org/10.1371/journal.pcbi.1008873.g003
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the active site: the non-nucleoside inhibitor binding pocket (NNIBP) formed of several sites of
the p66 subunit as well as site 138 of the p51 subunit. Nucleoside RT Inhibitors (NRTI) are
nucleotide analogs and bind in the active site, blocking reverse transcription. Non-Nucleoside
RT Inhibitors (NNRTI) bind in the NNIBP, changing the protein conformation and blocking
reverse transcription. More details on the structure and function of HIV-1 RT can be found in
[38]. A general view of where the new mutations are situated with regards to the other impor-
tant sites of HIV-1 RT is shown in Fig 4, and is detailed below.
L228R/L228H. L228R is the most important of these new mutations according to the fea-
ture importance ranking done above. This is reflected in the very high over-representation in
RTI-experienced sequences and sequences with known RAMs shown in Table 3. When look-
ing at the detailed RRs shown in Fig 3, we observe that L228R presents high RR values with
mainly NRTI RAMs, but also with NNRTI RAMs such as Y181C and L100I, and this is even
more so for RRs computed on the African dataset (S1 Fig). L228H is very similar in all regards
to L228R, however its highest RRs are exclusively with NRTI RAMs.
Fig 4. Structure of HIV-1 RT with highlighted important sites. The p66 subunit is colored dark gray and the p51 subunit white. The active site is
highlighted in blue, and the NNIBP is highlighted in yellow. The sites of new mutations are colored in red.
https://doi.org/10.1371/journal.pcbi.1008873.g004
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Site 228 of the p66 subunit is located very close to the active site of RT, where NRTIs oper-
ate (Fig 4 and S3 Fig) which could explain the role that L228R and L228H seem to have in
NRTI resistance. However, site 228 of the p66 subunit is also between sites 227 and 229 which
are both part of the NNIBP. Furthermore, both L228H and L228R have very low BLOSUM62
score, of -3 and -2 respectively (Table 3). Arginine (R) and Histidine (H) are both less hydro-
phobic than Leucine (L), and have positively charged side-chains. This important change in
physicochemical properties could explain the role they both seem to have in NRTI resistance.
However, while both Arginine and Histidine are larger than Leucine, Arginine is also fairly
larger than Histidine, which is aromatic. This difference between both residues might explain
the association L228R seems to have with NNRTI resistance that L228H does not have.
E203K/H208Y. Both E203K and H208Y are highly over-represented in RTI-experienced
sequences and sequences with known RAMs. They both have high RR values for NRTI RAMs.
Furthermore the most highly valued RAM RRs in Fig 3, are very similar for E203K and
H208Y. Structurally they are close to each other on an alpha helix which is close to the active
site.
Both E203K and H208Y have positive, albeit not maximal, BLOSUM62 scores, meaning
they are fairly common substitutions. However, these mutations induce some change in physi-
cochemical properties with Tyrosine (Y) being less polar than Histidine (H), and the change
from Glutamic Acid (E) to Lysine (K) corresponding to a change from a negatively charged
side chain to a positively charged one.
All this, combined with their structural proximity and the shared high RR values for single
RAMs, suggests a similar role in NRTI resistance.
I135L. In Table 3 and Fig 3, we observe that I135L has the lowest RR values of all the new
mutations, with CI bounds lower than 2 in Table 3’s general RRs. However, it is the most prev-
alent of the new mutations. If we look at the detailed RRs of Fig 3, we see that I135L is signifi-
cantly over-represented in sequences with NNRTI RAMs, specifically A98G and P225H.
Structurally this makes sense: On the p66 subunit, site 135 is on the outside, far from both the
active site and the NNIBP. However, site 135 on the p51 subunit is located very close to the
NNIBP (Fig 3 and S2 Fig).
The BLOSUM62 score for this substitution is quite high (Table 3), which is expected since
both residues are very similar to one another, differing only by the positioning of one methyl
group. However, Leucine (L) is less hydrophobic than Isoleucine (I), despite they are still both
classified as hydrophobic residues (S1 Table).
The proximity between site 135 and the pocket in which NNRTI RAMs bind, as well as the
high RR values for these NNRTI RAMs leads us to believe that I135L could play a subtle acces-
sory role in NNRTI resistance, either by enhancing the effect of some NNRTI RAMs (typically,
A98G and P225H), or by compensating for loss of fitness.
D218E. D218E is also highly over-represented in both RTI-experienced sequences and
sequences with known RAMs. It has infinite RR values in the African dataset (Table 3),
because it is quite rare in this dataset, and all of its 25 occurrences are in sequences that have
at least one known RAM and are RTI-experienced. In fact, from the UK dataset we can see
that D218E has some of the highest RR values for individual RAMs (along with H208Y).
The majority of these very high RR values occur for NRTI RAMs. Site 218 on the p66 sub-
unit is quite close to the RT active site, which could explain the role D218E seems to have
in NRTI resistance. Aspartic acid (D) and Glutamic acid (E) are very similar amino acids,
both acidic with negatively charged side-chains, as reflected in their fairly high BLOSUM62
score, the main difference between both being molecular weight, with E being slightly larger
than D.
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Discussion and perspectives
Our method has allowed us to identify six mutations that might play a role in drug resistance
in HIV. These mutations are significantly over-represented in RTI-experienced sequences, as
well as sequences exhibiting at least one other known RAM. The fact that models trained on
the UK are still performant on such a different dataset as the African one strongly suggests that
the learned classifier models have acquired generalized knowledge on resistance. For all of
these new mutations their spatial positioning on HIV-1 RT is consistent with our conclusions,
as all were either close to the active site or the regulatory binding pocket.
Some of the mutations we have identified as potentially associated with resistance have
been mentioned in previous studies. L228R/H have been observed before [39] and were sug-
gested to be associated with reduced susceptibility to didanosine [40, 41]. I135L has been
observed in sequences with reduced susceptibility to NNRTIs [42]. H208Y has been associated
with NNRTI and NRTI resistance [43] and it has been suggested that it has an accessory role
in NRTI resistance [44]. E203K, D218E, L228RH and H208Y have all been mentioned in [45]
as probably linked to phenotypic resistance to NRTI and NNRTI.
However, none of these mutations has been experimentally confirmed as conferring
or helping with drug resistance to the best of our knowledge. The fact that we find them
again with a big data analysis of highly different sequences and involved statistical
selection procedure combining multiple testing and machine learning, and that we have
very high significance, clearly indicates their potential role in resistance. Therefore, we
believe they are sufficiently linked to drug resistance that they garner a closer inspection
either in-vitro or in-vivo to determine the mechanisms that could allow them to play a role
in resistance.
With our machine classifiers we seem to have found some RAMs of an accessory nature,
over-represented in sequences already containing known RAMs. This is a form of epistasis,
where the interaction between the main RAM and the accessory RAM is important. How-
ever, we did not manage to find subtler forms of epistasis, in our dataset, where two muta-
tions separately have no effect on resistance but have an effect together. This is partly
indicated by the fact that there is a limited performance gap between the Fisher exact tests
and more sophisticated classifiers, that are able to reveal significant association of mutations,
while each individual mutation has low prediction power. However, one advantage of
machine learning classifiers, is that they are probabilistic, meaning that they can give more
nuanced insights into the nature or resistance level of a given sequence than the classical
binary presence/absence of RAMs approach. In this regard logistic regression appears as a
method of choice, showing similar or better performance than other classifiers, and an easy
interpretation that is facilitated by the lasso regularization which performs a simple feature
selection and retains the most important ones. Similar results were already observed on
other sequence analysis tasks [46]. In order to investigate the second form of epistasis further
we tested each pair of mutations in the UK dataset (n = 867, 903) with Fisher exact tests to
see if they were linked to treatment status. In order to mitigate the effects of phylogenetic
correlation which are sure to have an effect in this type of setting, we tested the pairs that
were significantly associated to treatment (n = 1, 309) again on the African dataset. We also
compared these results to the Fisher exact tests executed for each single mutation. We did
not find any pair of mutations that was significantly associated to treatment, where neither
member were significantly associated individually. Moreover, we only found 3 significantly
associated pairs of mutations that did not include at least one known RAM, and they all
included one of our newly found potential RAM: L228R + I142V, L228R + F214L and
L228H + F214L (see S2 Appendix for details).
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With therapeutic strategies targeting multiple proteins that are now used, there might be
some epistatic effects with other regions of the HIV genome that are targeted by some of the
drugs. These potential effects however, lie outside the scope of this study.
Because of the lack of detailed treatment history metadata, we did not distinguish mutations
arising from NRTIs or NNRTIs. We believe that a large amount of high quality sequence data,
along with a sufficiently detailed log of treatments and drugs the sequences were exposed to,
could allow us to use our machine-learning approach to find mutations related to specific
drugs and thus furthering our knowledge of HIV drug resistance, giving clinicians more tools
to manage and help infected patients.
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S1 Appendix. Technical appendix. Technical details about the implementation and options
for used tools.
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S2 Appendix. Fisher exact tests on pairs of mutations. A detailed explanation of the proce-
dure followed to test pairs of mutations for association with treatment. Detailed numerical
results are also given.
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S1 Fig. Relative risks of the new mutations with regards to known RAMs on the African
dataset. (i.e. the prevalence of the new mutation in sequences with a given RAM divided by
the prevalence of the new mutation in sequences without the RAM). RRs were only computed
for mutations (new and RAMs) that appeared in at least 30 sequences, which is why RRs were
not computed for H208Y and D218E. 95% confidence intervals, represented by vertical bars,
were computed with 1000 bootstrap samples of the African sequences. Only RRs with a lower
CI boundary greater than 2 are shown. The shape and color of the point represents the type of
RAM as defined by Stanford’s HIVDB. Blue circle: NRTI, orange square: NNRTI, green dia-
mond: Other. For the RR of L228H with regards to M184V, the upper CI bound is infinite.
The new RAMs have high RR values for known RAMs similar to those obtained on the UK
dataset. We also arrive at similar conclusions, I135L being associated with NNRTIs, E203K
and L228H to NRTI and L228R to both. RR values are shown from left to right, by order of
decreasing values on the lower bound of the 95% CI.
(EPS)
S2 Fig. Closeup structural view of the entrance of the NNIBP of HIV-1 RT. The p66 subunit
is colored in dark gray, the p51 subunit in light gray. The NNIBP is highlighted in yellow. The
active site is colored in blue. We can see the physical proximity of I135 (red) to the entrance of
the NNIBP. We can also see how L228 (red) is between 2 AAs of the NNIBP.
(PNG)
S3 Fig. Closeup structural view of the active site of HIV-1 RT. The p66 subunit is colored in
dark gray, the p51 subunit in light gray. The active site is highlighted in blue. The NNIBP is
colored in yellow. L228, E203 and D218 (red) are also very close on either side of the active
site.
(PNG)
S1 Table. Detailed table of “new mutation” characteristics.
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21. Riemenschneider M, Senge R, Neumann U, Hüllermeier E, Heider D. Exploiting HIV-1 Protease and
Reverse Transcriptase Cross-Resistance Information for Improved Drug Resistance Prediction by
Means of Multi-Label Classification. BioData Mining. 2016; 9(1):10. https://doi.org/10.1186/s13040-
016-0089-1 PMID: 26933450
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